# Immunomodulatory Effects of PCSK9 Inhibition

> **NCT05720156** · — · WITHDRAWN · sponsor: **Massachusetts General Hospital**

## Conditions studied

- Atherosclerotic Cardiovascular Disease
- Cardiovascular Diseases
- Atherosclerosis
- Arterial Inflammation
- Vascular Diseases
- Vascular Disease, Peripheral
- Vascular Calcification
- High Cholesterol/Hyperlipidemia
- Heart Diseases
- Heart Attack
- Stroke
- Cerebrovascular Accident
- Carotid Artery Diseases
- Carotid Atherosclerosis
- Transient Ischemic Attack

## Interventions

- **OTHER:** 99mTc-tilmanocept SPECT/CT scanning

## Key facts

- **NCT ID:** NCT05720156
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-04
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of Feasibility
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720156, "Immunomodulatory Effects of PCSK9 Inhibition". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05720156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*